Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

ting stent with clinically important benefits for patients," said Gregg W. Stone, M.D., Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III U.S. pivotal clinical trial for XIENCE V.

Clinical Data Supporting XIENCE V

The robust clinical program for XIENCE V includes long-term data from a total of 1,362 patients enrolled in the SPIRIT FIRST, SPIRIT II and SPIRIT III trials, as well as continued access and post-approval programs that will enroll more than 14,000 XIENCE V patients.

The FDA approved XIENCE V based, in large part, on superior results from the 1,002 patient SPIRIT III U.S. pivotal clinical trial, in which XIENCE V demonstrated statistical superiority to TAXUS on the study's primary endpoint of in-segment late loss (vessel renarrowing) at eight months, with a statistically significant 50 percent reduction (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS). XIENCE V also demonstrated statistical non-inferiority to TAXUS in the co-primary endpoint of target vessel failure (TVF, cardiac events related to the stented vessel) at nine months, with an observed 20 percent reduction (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS). TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

In May 2008, Abbott presented two-year data from the SPIRIT III trial demonstrating that XIENCE V continues to deliver positive clinical benefits for patients. At two years, the XIENCE V demonstrated the following key results:

-- A 45 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for TAXUS, p-value=0.004)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (MI) or ischemia-driv
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 His Majesty Willem-Alexander, ... , The Court of His Majesty Willem-Alexander, King of ... the Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY ... 3. , The King will take part in the ... scheduled for 11 a.m.-12:20 p.m. and tour the plant. ...
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/20/2014)... Grade school history lessons often have it that American ... whooping cough, chicken pox, influenza and tuberculosis brought to ... while estimates vary, about 20 million people lived in ... percent of them were killed by European diseases., But ... Arizona State University and Johannes Krause of the University ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... RATON, Fla., Feb. 17, 2011 Sensus ... participation in the 9th Annual South Beach ... 17-21, 2011.  The South Beach Symposium™ is a comprehensive ... and practice management. Sensus Healthcare is featuring superficial radiotherapy ...
... of Santiago de Compostela (USC) have analysed levels of radon, ... The results show that 34% of these schools exceed the ... inhalation of radon is associated with lung cancer. "Out ... had radon levels in excess of 400 Bequerels/m3 in some ...
... a significant component of the defense system of many ... armies and terrorist organizations, and constitute a threat to ... solutions against them have limited efficiency. A multidisciplinary ... succeeded in developing an enzyme that breaks down such ...
Cached Biology Technology:Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™ 234 percent of Galician secondary schools exceed maximum recommended radon levels 2Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 2Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 3Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 4
(Date:8/21/2014)... implications for life in other extreme environments, both on ... Associate Professor of Biological Sciences Brent Christner and fellow ... this week published a paper confirming that the waters ... (2600 feet) beneath the surface of the West Antarctic ... than 400 subglacial lakes and numerous rivers and streams ...
(Date:8/21/2014)... to Wednesday, Oct. 18-22, 2014 , WHERE: ... Drive, San Diego, CA 92101 , WHAT: ... presentations of the latest research in human genetics. ... featuring high-scoring abstracts on rare genetic variants in ... and treatment for sun sensitivity (Saturday, Oct. 18, ...
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
Breaking Biology News(10 mins):800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4American Society of Human Genetics 2014 Annual Meeting 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... Washington, D.C. -- Disease statistics buried within patient ... and organized to depict geographic patterns, allowing the discovery ... Penn State geographer. "The use of interactive maps ... to greater insight into complex events like the spread ...
... region has a hot, wet climate and a lot of ... a really good chance the region will also contain numerous ... study examining the geography of human disease, led by Dr. ... team of biologists and social scientists, shows that that one ...
... world-wide project "MAGICPAH", coordinated by the Braunschweiger Helmholtz-Zentrums ... Braunschweig- HZI), is examining how bacterial communities are ... aromatic hydrocarbons. "MAGICPAH" is a collaboration of thirteen ... enterprises have initiated the project today at the ...
Cached Biology News:Visualization of geographic patterns may predict spread of disease 2Study pins factors behind geography of human disease 2Study pins factors behind geography of human disease 3Improving the degradation of toxic hydrocarbons 2
... The Beacon 2000 Fluorescence Polarization System ... research and assay development. Standard Beacon ... 2000 System uses a quartz-halogen lamp ... of 360-700 nm. It accommodates all ...
... traps a wide variety of solvent vapors that ... glass condensation flask (GCF400) allows for the collection ... easy draining. Rapid cooling time minimizes waiting period., ... quick solvent changes , -50?C ...
... Phosphatase-2A (PPase-2A) is a serine/threonine phosphatase isolated ... isolated as the heterodimer of 60kDa (A) ... ability to dephosphorylate the a-subunit of phosphorylase ... has broad substrate specificity and may play ...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Biology Products: